Taken together, these results indicated that NZ001, a multitargeting RTK inhibitor that blocks both MET and VEGF signaling, has more significant inhibitory effect on tumor growth without inducing invasion and metastasis frequently observed after sorafenib treatment. This evidence concerns the gene MET and neoplasm.